8-K: Keros Therapeutics Announces Participation in Upcoming Healthcare Conferences

Keros Therapeutics' Chair and CEO, Jasbir Seehra, will participate in fireside chat presentations at the TD Cowen and Leerink Partners healthcare conferences in March 2025.

Summary

• Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its Chair and CEO, Jasbir S. Seehra, will participate in two upcoming healthcare conferences.
• Seehra will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 9:50 a.m. Eastern time.
• He will also present at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern time.
• Archived replays of the presentations will be available on the Keros website for 90 days following each event.
• Keros is focused on developing therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-) family of proteins.
• Their product candidates include elritercept (KER-050) for low blood cell counts, cibotercept (KER-012) for pulmonary arterial hypertension and cardiovascular disorders, and KER-065 for neuromuscular diseases.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive, indicating increased visibility for the company through conference participation. It doesn't contain any negative information.

Positives

• Participation in these conferences provides Keros with an opportunity to present its pipeline and strategy to a wider audience of investors and industry professionals.
• The availability of archived replays allows interested parties to access the presentations at their convenience.

Future Outlook

The company will present at two healthcare conferences in March 2025, offering insights into its pipeline and strategy.

Industry Context

Participation in healthcare conferences is a common practice for biopharmaceutical companies to raise awareness, attract investors, and network with industry peers. Keros' focus on TGF-beta signaling aligns with growing interest in targeted therapies for various diseases.

Stakeholder Impact

• Shareholders may benefit from increased awareness and potential investment in the company.
• The conferences provide an opportunity for Keros to engage with potential partners and collaborators.

Next Steps

• Jasbir Seehra will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025.
• Jasbir Seehra will present at the Leerink Partners Global Healthcare Conference on March 10, 2025.
• Archived replays of the presentations will be made available on the Keros website.

Key Dates